Amalia Gastaldelli is a Director of Research at the Institute of Clinical Physiology of the National Research Council (CNR) in Pisa, Italy , where she leads the Metabolic Diseases Group and the Multi-Omics Mass Spectrometry Laboratory. Since 2002, she has been an adjunct Professor of Medicine at the Diabetes Division of UT Health in San Antonio, Texas. Since 2018, she has been an adjunct professor at the Sant'Anna School of Advanced Studies in Pisa. Prof Gastaldelli is the president of the European MASLD Study Group, which is affiliated with the EASD, which she founded in 2012, and the president of the EGIR (European Group for the Study of Insulin Resistance) since 2018. She has been part of the EASL-EASD-EASO committees that wrote the 2016 and 2023 clinical guidelines for managing NAFLD/MASLD, and of the IDF Technical Working Group that wrote the 2025 IDF Global Clinical Practice Recommendations for Managing Type 2 Diabetes.
Prof. Gastaldelli has over 25 years of experience leading national and international scientific projects. She has published over 400 original articles and book chapters, and she has been recognised as a Highly Cited Researcher by Clarivate since 2023. She has participated in and partnered with numerous EU-funded projects investigating the pathophysiological mechanisms of metabolic diseases. These projects include the FP7 ‘FLIP’ (Fatty Liver Inhibition of Progression), the H2020 ‘EPOS’ (Elucidating Pathways of Steatohepatitis), the H2020-JTI-IMI2-2016 ‘LITMUS’ (Liver Investigation: Testing Marker Utility in Steatohepatitis), H2020-JTI-IMI2-2019 ‘SOPHIA’ (Stratification of Obese Phenotypes to Optimize Future Obesity Therapy) and the most recent HE-IHI-JU ‘GRIPonMASH’ (Global Research Initiative for Patient Screening on MASH) and HE ‘PAS-GRAS’ (De-risking metabolic, environmental and behavioural determinants of obesity in children, adolescents, and young adults).
Her team consists of biologists, chemists, bioinformaticians, and physicians. They employ state-of-the-art techniques and a translational approach to study human physiology. For instance, they employ mass spectrometry coupled with stable isotope tracers to assess glucose and lipid production and disposal, along with insulin resistance and secretion in vivo. They also use omics techniques, such as metabolomics, lipidomics, fluxomics, and exposomics, as well as AI techniques and mathematical models, to thoroughly evaluate metabolic alterations. She has also used imaging tools (such as MRI, CT, and ultrasound) to study body fat distribution (visceral, hepatic, cardiac, and muscular) and cardiac function. She has also used PET to study organ metabolism.
Duality of Interest: Professor Gastaldelli has received honoraria for advisory boards, lectures or other educational activities by Boehringer-Ingelheim, Echosens, Eli Lilly, Madrigal, MSD, Novo Nordisk, Pfizer, Regeneron.